drugset / Trial / NCT01268839
A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Phase 1
Completed
20 enrolled
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA · collab
NaSingle-groupOpen-label
Summary
The purpose of this study is to investigate the pharmacokinetics of TMC278 (rilpivirine) 25 mg once daily following a preceding 2-week treatment period with efavirenz 600 mg once daily in healthy volunteers
Timeline
- Start
- 2010-01
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | — |
| Subject | Rilpivirine | Small molecule | 25 mg | — |